Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels

The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferativ...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Smalley, K S M, Contractor, R, Haass, N K, Lee, J T, Nathanson, K L, Medina, C A, Flaherty, K T, Herlyn, M
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2007
Témata:
Translational Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2360037/
https://ncbi.nlm.nih.gov/pubmed/17245336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603596
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky